Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by HC Wainwright
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $46.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 47.44% from the company’s previous close. […]
More Stories
Trump Designates Fentanyl as Weapon of Mass Destruction
By Darlene McCormick Sanchez President Donald Trump signed an executive order designating fentanyl as a weapon of mass destruction during...
Rob Reiner’s Son Booked for Murder After Director, Wife Found Dead
By Zachary Stieber Nick Reiner has been taken into custody following the death of his parents, Rob and Michele Reiner....
Tomorrow’s Jobs Report to Test the Resilience of the US Labor Market
By Andrew Moran The November jobs report will be released on Dec. 16, revealing the health of the U.S. labor...
US Officials Identify National Guardsmen Killed in ISIS Attack in Syria
By Jack Phillips The two U.S. military members killed over the past weekend in central Syria were Iowa Army National...
Police Detain Person of Interest in Deadly Brown University Shooting
By Jacob Burg A person of interest is in custody over the shooting at Rhode Island’s Brown University on Saturday...
Trump Honors US ‘Miracle on Ice’ Hockey Team in White House Celebration
By Travis Gillmore WASHINGTON—President Donald Trump hosted members of the 1980 U.S. Olympic hockey team at the White House on...